Import Alert 54-16 lets FDA detain products sold as foods or dietary supplements from listed firms without examining them when testing has found a drug ingredient inside. Sexual enhancement, weight loss and muscle building products are the most common. Removal takes analytical data and labels that show the drug is gone for good.
Listed on 54-16? Send us the firm name, product and ingredient found. We review the finding and plan the removal request.
Get a 54-16 Case Review| Item | Import Alert 54-16 |
|---|---|
| Official title | DWPE of Products Marketed as Foods, Including Dietary Supplements, That Contain an API |
| Drug charges | Unapproved new drug 505(a); misbranded 502(f)(1) |
| Food charges | Poisonous 402(a)(1); unsafe food additive 402(a)(2)(C) |
| Removal review | FDA reviews analytical data, labels and labeling |
| Countries | 19 countries and territories on the Red List |
| Removal contact | Importalerts2@fda.hhs.gov |
Details follow the current text of Import Alert 54-16, published October 15, 2026.
Capsules, honey sachets and coffees with sildenafil-type PDE-5 drugs.
Slimming products with sibutramine and similar drugs.
Products with anabolic steroids or novel synthetic steroids.
Products with prescription NSAIDs such as indomethacin.
Royal honey and honey-based products with drug ingredients.
Herbal pastes, teas and botanicals with added drugs.
| Drug type | Example |
|---|---|
| PDE-5 inhibitors | Sildenafil |
| Withdrawn drugs | Sibutramine |
| Anticoagulants | Warfarin |
| Anticonvulsants | Phenytoin |
| Statins | Lovastatin |
| Prescription NSAIDs | Indomethacin |
| Beta-blockers | Propranolol |
| Controlled substances | Benzodiazepines, anabolic steroids |
The alert does not set a release testing protocol. The owner or consignee presents evidence that the product complies, usually lab analysis and labeling, to the FDA Division compliance office named in the notice of detention. A product with a drug ingredient cannot be sold as a supplement.
Evidence the conditions behind the violation are resolved, including analytical data, labels and labeling for FDA to review, emailed to Importalerts2@fda.hhs.gov under RPM Chapter 9-8.
Need samples pulled and tested for a detained supplement shipment? Our sister company, FDA Detention Sampling, coordinates sample collection, chain of custody and testing with LAAF-accredited laboratories nationwide. Call +1 (786) 561-3726.
FDA's framework is in RPM Chapter 9-8; FDA removal guidance explains what a request should include.
Removal help for food and supplements.
Supplement registration and labeling.
Check claims and ingredient labeling.
Illegal and undeclared colors.
Heavy metals in food and supplements.
FDA hold statuses and release steps.
We review the drug finding, trace the root cause, plan new lot testing and prepare the removal request. We are an independent compliance firm, not FDA or a law firm, and no one can guarantee FDA's decision.
Contact our specialists, email info@fdaregistrationassistance.com, or call +1 (928) 275-8333. Import alert removal · Supplement services · Contact.
Get a 54-16 Case ReviewFDA Registration Assistance is a private consulting firm, not FDA or any government agency. FDA registration is not FDA approval, clearance or certification.
Import Alert 54-16 is titled "Detention Without Physical Examination of Products That Are Marketed as Foods, Including Products Marketed as Dietary Supplements, That Contain an Active Pharmaceutical Ingredient." It lets FDA detain listed products without examining each shipment because earlier testing found drug ingredients.
The alert names PDE-5 inhibitors such as sildenafil, withdrawn drugs such as sibutramine, anticoagulants such as warfarin, anticonvulsants such as phenytoin, statins such as lovastatin, prescription NSAIDs such as indomethacin, beta-blockers such as propranolol, controlled substances including benzodiazepines and anabolic steroids, and novel synthetic steroids.
Products promoted for sexual enhancement, weight loss and muscle building, plus honey and royal honey products, herbal coffees, slimming teas, herbal pastes and vitamin and mineral products. The Red List covers 19 countries and territories.
If the labeling shows drug use, the product is charged as an unapproved new drug under section 505(a) and a misbranded drug under section 502(f)(1). If it does not, it is charged as adulterated food under section 402(a)(1) (poisonous or deleterious substance) and section 402(a)(2)(C) (unsafe food additive). Refusal is under section 801(a)(3).
FDA says these APIs are not safe except under the supervision of a licensed practitioner. A product that contains the same ingredient as an approved drug, or an analogue of it, cannot be sold as a food or supplement unless it is covered by an approved application.
No. An ingredient approved as a drug generally cannot be in a dietary supplement. The product would need FDA drug approval to be sold legally. See our dietary supplements page.
Open Import Alert 54-16 and search the Red List by country and firm name. Each entry shows the product and the date it was added. Check before every shipment season, since the alert is updated often.
The alert does not set a release testing protocol. The owner or consignee can present evidence such as lab analysis and labeling to the FDA Division compliance office named in the notice. A product that actually contains a drug ingredient will not be released as a supplement.
Submit evidence that the conditions that caused the violation have been resolved, so FDA can be confident future entries will comply. FDA says it reviews the analytical data, labels and labeling sent in support of removal. Send the request to Importalerts2@fda.hhs.gov.
A root cause investigation showing how the drug got into the product, the reformulated product, new supplier and contract manufacturer controls, lab analysis of new lots for the API and its analogues, and revised labels with no drug claims.
FDA found that many products contain analogues of approved drugs, chemically altered versions that standard tests may miss. A testing plan should cover the drug class, not just one compound.
Some firms on 54-16 were previously listed on Import Alert 54-08, which has been deactivated, for the presence of digitalis.
Removal requests go to Importalerts2@fda.hhs.gov. The alert lists the Division of Import Operations at (301) 796-0356 and FDAPRIVATELABIMPORTALERTS@fda.hhs.gov for sampling and analytical methods.
Importers must keep a Foreign Supplier Verification Program that covers undeclared drug ingredients where it is a known or reasonably foreseeable hazard, with supplier verification and testing for higher-risk products. See our FSVP service.
No. FDA makes every removal decision. We are an independent compliance firm, not FDA or a law firm. We help you build a complete, well-documented request.
Tell us what your company makes, sells, or distributes, where each product is manufactured or packed, your U.S. importer or buyer arrangement, label readiness, and target shipment date.
Submitting this inquiry does not purchase a service or authorize paid work. Our team can discuss the scope and required materials before you commission assistance. Fields marked with an asterisk are required.